The Point of Care Diagnostics Market Forecast 2014-2024

LONDON, April 16, 2014 /PRNewswire/ --

Future Prospects for Leading Companies 

Point of care diagnostics - discover technological and commercial prospects
What does the future hold for the point of care diagnostics market? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 308 page report provides 173 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT, Porter's Five Forces and PESTEL), company profiles and commercial developments. Read the full transcripts of four exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
• Dr. Terenzio Facchinetti, Director Business Development, UL International GmbH
• Dr. Keith Batchelder, CEO and Founder of Genomic Healthcare Strategies (GHS), USA
• Dr. David Huckle, President and CEO of Adams Business Associates (ABA), UK
• Dr. Stephan Cohen-Bacrie, Co-director of the Multi-site Laboratory of Immunohematology and Immunogenetics, French Blood Establishment

You will find prospects for key submarkets
In addition to analyses of the overall world market, you will see revenue forecasting of seven world-level submarkets to 2024:
• Blood glucose testing market
• Coagulation testing market
• Cardiac marker testing market
• Infectious diseases testing market
• Pregnancy testing market
• Cholesterol testing market
• Other point of care diagnostics markets

In general, each submarket is further segmented by components and discussions for leading regional markets within each submarket are also provided.

Our investigation shows business research and analysis with individual revenue forecasts and discussions. How will the point of care diagnostic markets expand? This study will allow you to thoroughly understand the industry, finding the most promising places for investments and sales.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

What are the prospects in the leading regions and countries?
Events and progress worldwide will influence the market. In our study you will find individual revenue forecasts to 2024 for 15 national markets:
• US
• Japan
• Germany
• UK
• France
• Italy
• Spain
• Netherlands
• Belgium
• Switzerland
• Brazil
• Russia
• India
• China
• South Korea
• RoW

Many opportunities exist within the point of care diagnostics market. Greater uptake of existing technology and products worldwide will also stimulate the industry and market. With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what is likely to achieve the most success.

Additionally, you will find individual revenue forecasts to 2024 for 15 leading IVD national markets:
• US
• Germany
• France
• Italy
• Spain
• UK
• Netherlands
• Belgium
• Switzerland
• Japan
• China
• India
• South Korea
• Brazil
• Russia
• Row

Leading companies and potential for market growth
Overall world revenue for the point of care diagnostics market will reach $17.2bn in 2014, our work forecasts. We predict strong revenue growth from 2014 to 2024. Our work shows you what organisations hold greatest potential. See profiles of four leading companies, including these:
• Roche
• Abbott
• Siemens
• Alere

In general, a company profile gives you the following information:
• Overview of the company, including its history in the market
• Revenue forecasts from 2014 to 2024
• Discussion of a company's activities and outlook including descriptions of leading products
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, inc. alliances, partnerships and joint ventures

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

What issues will affect the point of care market?
Our new report discusses issues and events affecting the point of care market. You will find discussions, including qualitative analyses:
• An ever-growing patient population with chronic diseases
• An aging population
• Globalisation of infectious diseases and associated public health concerns
• Increasing demand for better monitoring and control of diseases
• Telehealth and remote communications between diagnostics and laboratories
• Global focus on personalised medicine

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How The Point of Care Diagnostics Market Forecast 2014-2024: Future Prospects for Leading Companies report helps you
In summary, our 307 page report gives you the following knowledge:
• Revenue forecasts to 2024 for the overall world point of care diagnostics market and 7 submarkets - discover the industry's prospects, finding promising places for investments and revenues
• Assessment of leading companies, and others, discovering activities and outlooks
• Market forecasting to 2024 for 15 leading regions and countries in the POC diagnostics market and IVD market - USA, Japan, Germany, France, UK, Spain, Italy, Netherlands, Belgium, Switzerland, Brazil, Russia, China, India, South Korea and RoW.
• View opinions from our survey, seeing 4 interviews with leading authorities
• Investigation of competition and opportunities influencing sales
• Discussion of what stimulates and restrains the point of care diagnostics market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

visiongain's study is for everybody needing commercial analyses for the point of care diagnostics market. You find data, trends and predictions. Please order our report now.

To request a report overview please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1237/The-Point-of-Care-Diagnostics-Market-Forecast-2014-2024

Companies Listed in this report: 

1 Step Detect Associates
3M
3test
77 Elektronika Kft
Abaxis Inc
Abbott
Abbott Diagnostics
Abbott Laboratories
Abbott Point of Care
AbbVie
AccuBioTech Co., Ltd.
Accumetrics
Accutech
Acon Laboratories
Acrongenomics Inc.
Adams Business Associates (ABA)
Advanced Care
Advanced Liquid Logic
Advanced MicrodevicesPvt. Ltd.
Aerscher Diagnostics
AgaMatrix Inc.
Agendia
Aimedics (Australia)
Akers Biomedical
Alere Inc.
Alfa Scientific Designs, Inc.
Alfa Wassermann Diagnostic Technologies, LLC
All Medicus
Alliance International Co., Ltd.
Amedica Biotech
American Bio Medica Corp
AmeriTek
Amgenix International Inc
AMICAS Corp
Ampcor
Analyticon Biotechnologies AG
Ani Biotech
Ani Biotech/Ani Laboratories
Answer
Apex Biotechnology Corp.
Applied Microarrays
ARJ Medical
ARKRAY, Inc.
Arlington Scientific, Inc.
Artron Laboratories
AspenBioPharma, Inc.
Astra Zeneca
Ativa Medical
Atlas Genetics
Atlas Link Biotech Co., Ltd.
Atonomics A/S
Audit Diagnostics
Autobio Diagnostics Co., Ltd.
Aventir Biotech
Aware Oral OTC - Calypte Biomedical
Axis-Shield plc
Axxin
AZOG, Inc.
B.R.A.H.M.S. AG
Bain Capital
Barr Pharmaceuticals
Bayer
BBI Healthcare
Bbraun
BC Partners
BD Biosciences
Beckman Access
Beckman Coulter Inc.
Becton, Dickinson and Company (BD)
Bio-AMD
Biofire Diagnostics
BioHelix Corporation
bioLytical Laboratories
BioMeditech Corporation
BioMerieux
Bionime
Bio-Rad Laboratories Inc.
BioSign
Biosite
Blackstone Group
Boditech
Boditechmed
Boehringer Ingelheim
Buying Solutions
C8 Medisensor
Calypte Biomedical Co
Cantimer
CardioGenics
Carlyle Group
Cepheid
CHEMBIO DIAGNOSTIC SYSTEMS, INC
Chugai Pharmaceuticals
Church & Dwight (CHD)
Clearview
CLIA laboratory
CoaguSense
Core Diagnostics
Dade Behring
Daktari Diagnostics
Danaher
Danaher Corporation
Decision Diagnostics Corp.
Dexcom
Diabetic Supply of Suncoast
Diagnostic Devices
Diagnostics for the Real World
DiME
e2v Biosensors
Early Pregnancy Tests.com
EIDIA
Eisai
EKF-diagnostic Gmb
Entegrion
Entra Health Systems
Epocal Inc
Expression Diagnostics
EY Laboratories
Fifty50 Medical
First Medical
Fisher Scientific
Focus Diagnostics
Fora Care
GeneDiagnostics Inc.
Genentech
General Life Biotechnology Ltd
Genesis Health Technology
Genomic Healthcare Strategies (GHS)
Genzyme
GlaxoSmtihKline (GSK)
Gluco Com
Grifols
Helena Laboratories
Helena Point of Care
Hema technologies
HemoCue
Hologic Inc
Home Diagnostics, Inc. (HDI)
Horiba
Ibis Biosciences
IDEV Technologies
IME-DC
Immucor
IND Diagnostics
Infopia
Innotrac
Insight Pharmaceuticals
Instrumentation Laboratory
Integrity Applications Ltd.
Inverness Medical Innovations (Alere)
IQuum
JANT Pharmacal Corporation
Johnson & Johnson (J&J)
Johnson & Johnson LifeScan
Johnson & Johnson's Ortho Clinical Diagnostics unit (OCD)
KKR & Co
Leeds and Partners
Lifescan Inc.
LifeSign
MBio Diagnostics
Mechanical Heart Valve Support Group
Medco Health Solutions
Medix Biochemica
Medmira Inc
Medtronic Ltd
Meikang Biotech
Menarini
Mendor
Merck
Meridian Bioscience
Micronics (acquired by Sony Corporation)
Mitsubishi Chemical
Mitsubushi Chemical Medience
MIZUHO MEDY Company
MobileLink
MyoCheck
NanoEntek
Nanogen
Nanomix, Inc.
Nanosphere, Inc.
Nestle
Nipro Diagnostics
Nova Biomedical
Novartis AG
Novescia Network of laboratories
Oak Tree International Holdings
Olympus
OnSight
OptiMedica Corporation
OraSure Technologies, Inc.
OrSense
Ortho-Clinical Diagnostics
Partec
Partec GmbH
PathWorks Diagnostics
Pfizer
PharmaTech Solutions, Inc.
PointCare Technologies Inc
Polymer Technology Systems Inc
Portola Pharmaceuticals
Procter and Gamble (P&G)
Prometheus Laboratories
Proteome Systems
Qiagen N.V.
Quest Diagnostics
QuickMedical
Quidel Corporation
Radiometer Medical ApS
Remel
Response Biomedical Corporation
Roche
Roche Diabetes Care (RDC)
Roche Diagnostics Corporation
Roche Holdings
Royal Philips Electronics
Runbio Biotech Company
SA Scientific
Sanofi
Savyon Diagnostics
Sekisui Medical Company
Siemens
Siemens AG
Siemens Diagnostics
Siemens Healthcare Diagnostics
Spirit Healthcare
STARLIMS Technologies
Suyog Diagnostics
Swiss Precision Diagnostics GmbH (SPD)
Symphony
Sysmex
SysmexCorporationThermo Scientific
T2 BioSystems
Teva
Therapeomics
Thermo Cardiosystems
Thermo Electron Corporation
Thermo Fisher Scientific Inc
Thoratec Corporation
Tocagen
Transasia Bio-Medicals
Triage
Trinity Biotech
Trovagene
U.S. Diagnostics
UL International GmbH
Universal Biosensors (UBI)
Universal Diagnostics
Ventana
Vermillion
Wall Greens
Wal-mart
Warburg Pincus
Wave 80 Biosciences
Werfen Group
Wilex
YD Diagnostics
Ypsomed
Zyomyx

Other Organisations Mentioned in This Report
American Diabetes Association
American Heart Association (AHA)
American Screening Corporation
AntiCoagulation Europe
AntiCoagulation Self-Monitoring Alliance (ACSMA)
Atrial Fibrillation Association
Baylor College of Medicine
Burnet Institute
Cambridge Sensors Limited
Centers for Device and Radiological Health (CDRH)
Centers for Disease Control and Prevention (CDC)
Centers for Medicare & Medicaid Services (CMS)
Children's Heart Federation
Clinical Laboratory Improvement Amendments (CLIA)
College of American Pathologists
Constitution Medical Investors
Department of Health and Human Services (HHS)
EU Council Directive
EU Notified Body
European Commission
European Diagnostics Manufacturers Association (EDMA)
Federal Joint Committee
Food and Drug Administration (FDA)
French Blood Establishment
Gemeinsamer Bundesausschuss
German Federal Ministry of Health
Harvard Salud Integral
In Vitro Diagnostic Device Evaluation and Safety (OIVD)
International Self-Monitoring Association of Oral Anticoagulated Patients (ISMAAP)
International Technidyne Corporation (ITC)
Japan's Ministry of Health
La Federación Española de Asociaciones de Anticoagulados (FEASAN)
Massachusetts General Hospital
MATCH Group
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mount Sinai School of Medicine
National Health Service (NHS)
National Innovation Centre
National Institutes of Health (NIH)
Northwestern Global Health Foundation
Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
Princenton BioMedtech
The Atrial Fibrillation Association
The Bill & Melinda Gates Foundation
The Centers for Disease Control and Prevention
The Centre for Disease Control (CDC)
The Children's Heart Federation
The College of American Pathologists
The European Directive
The European Society of Cardiology
The International Diabetes Federation (IDF)
The MATCH Group
The Mechanical Heart Valve Support Group
The National Institute for Health and Clinical Excellence (NICE)
The PATH's Diagnostics Group
UNAIDS
Unimed International
UNITAID
Universidad Peruana Cayetano Heredia
University of California
University of Cape Town and National Health Laboratory Service
US Department of Defense (DoD)
World Health Organization (WHO)
WorldCare International Clinical Trials

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com